First-in-human trial primes immune system to accept donor livers

medicalxpress - UPMC and University of Pittsburgh clinician-scientists have weaned and kept multiple liver transplantation patients off of all immunosuppressant drugs for more than three years through a first-in-human clinical trial of a unique "immune priming" therapy.

AI Summary: A first‑in‑human study reports a novel immune‑priming approach that enabled three liver transplant recipients to stop standard lifelong immunosuppression. The intervention appears to induce tolerance to donor tissue, reducing dependence on anti‑rejection drugs and their toxic side effects, offering a potential shift in transplant management if larger trials confirm these early results.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Experimental therapy significantly reduces Parkinson’s toxic protein in early trial / 7 wks

BioMarin Phase 3 failure dims hopes for rare‑disease therapy / 8 days

Insmed shelves Brinsupri in skin indication after mid‑stage flop / 7 wks

Sanofi ousts Paul Hudson as Belén Garijo named incoming CEO / 3 months

Stem cells show potent promise as a diabetes treatment / 8 days

Mid‑stage Parkinson trial failure halts drug development plans / 8 days

FDA clears AstraZeneca’s new blood-pressure drug baxdrostat / 13 days